• First human study of IMM-101 conducted in patients with an advanced form of the skin cancer, melanoma, which had spread beyond the primary site to confirm safety of the intended dose
• At the clinical investigator’s request, it was agreed that patients could continue to receive IMM-101 on a long-term basis. In order to provide continuous treatment for these patients they were offered inclusion to a Compassionate Use Programme. 
• Of the 18 patients enrolled* in the original study, 9 remained alive in 2018, more than 8 years later, with 4 of those still participating in the follow-up trial
• As two-thirds of patients had Stage IV metastatic disease these survival figures exceeded expectations

^{* one additional patient enrolled but withdrew early due to ineligibility}